Treatment of ARDS and hyperinflammation in COVID-19 with IL-6 antagonist Tocilizumab: a tertiary care experience from Pakistan

AUTHORS

1. Nosheen Nasir *FRCP (Edin), FCPS (IM) FCPS (ID), MSc (corresponding author)*
Assistant Professor, Dept. of Medicine
Aga Khan University
Stadium Road, Karachi 74800
Pakistan
Email: Nosheen.nasir@aku.edu
Phone: +92233332133936
9221-34930051 ext 4574
2. Syed Faisal Mahmood *DABID*
Associate Professor, Dept. of Medicine
Aga Khan University
Stadium Road, Karachi 74800
Pakistan
3. Kiren Habib *FCPS (IM)*
Senior Instructor, Dept. of Medicine
Aga Khan University
Stadium Road, Karachi 74800
Pakistan
4. Iffat Khanum *FCPS (ID)*
Senior Instructor, Dept. of Medicine
Aga Khan University
Stadium Road, Karachi 74800
Pakistan
5. Bushra Jamil *FRCP*
Professor, Dept. of Medicine
Aga Khan University
Stadium Road, Karachi 74800
Pakistan

RUNNING TITLE: Treatment of ARDS and hyperinflammation in COVID-19 with Tocilizumab

ABSTRACT

Cytokine release syndrome in COVID-19 is characterized by hyperinflammation which manifests as ARDS, multi-organ failure, and high inflammatory parameters. Tocilizumab, an IL-6 antagonist has been used in COVID-19 acute respiratory distress syndrome (ARDS) with conflicting results from different parts of the world. We conducted a retrospective descriptive study from Feb 2020 to May 2020 on COVID-19 patients with ARDS and hyperinflammation characterized by raised CRP and/or ferritin. A total of 244 patients with COVID-19 were admitted out of which 107 had ARDS. Thirty patients had both ARDS and hyperinflammation and received tocilizumab. The mean age was 62.5 years (SD: 13.5) and the majority were male (83%). The mean CRP pre-treatment was 217.5 mg/L and post 48 to 72 hours of tocilizumab treatment was 98.5 mg/L. Twenty-one patients (70%) also received concomitant intravenous methylprednisolone. Of the 30 patients, 7 died and 20 recovered. Ten patients required intensive care unit admission and nine developed nosocomial infections. COVID-19 associated aspergillosis was diagnosed in three patients post tocilizumab treatment. Mortality was significantly higher in patients who developed a nosocomial infection and who required intermittent positive pressure ventilation (IPPV). Our study is the first to describe the treatment outcomes with tocilizumab from a low-middle income country. The availability and cost of tocilizumab in our region which makes it imperative to understand its potential for use in our setting. Our study supports the use of tocilizumab in a select patient population with COVID-19 and recommends monitoring of nosocomial infections and opportunistic infections.

Key words

Cytokine release syndrome; Hyperinflammation; COVID-19; ARDS; IL-6; Tocilizumab

INTRODUCTION

COVID-19 was announced as a pandemic by the World Health Organization in March 2020¹ and since then it has infected 5,113,706 people globally and resulted in 330,361 deaths as of date². The life-threatening manifestation of COVID-19 is acute respiratory distress syndrome (ARDS) and is associated with significant morbidity and mortality³. The underlying pathogenesis of ARDS involves a dysregulated immune response leading to a cytokine release syndrome (CRS), referring to an excessive and uncontrolled release of pro-inflammatory cytokines. CRS in COVID-19 is characterized by hyperinflammation which manifests as ARDS, multi-organ failure, and high inflammatory parameters⁴. Key in the development of the CRS is an exaggerated release of the proinflammatory cytokine Interleukin-6 (IL-6) and elevated IL-6 levels correlate with ARDS⁵. Marked elevation of C-Reactive Protein (CRP) (whose expression is propelled by IL-6) also serves as a biomarker to assess the severity of clinical CRS³ and studies have used CRP and ferritin as surrogate markers of hyperinflammation^{6,7}.

Given the pivotal role of IL-6; it has been postulated that targeting IL-6 with available IL-6 inhibitors like tocilizumab may lead to clinical suppression of the CRS⁸. Data from clinical studies have been conflicting with regards to the efficacy of tocilizumab in COVID-19 ARDS. While limited studies from China have shown improved outcomes in COVID-19 patients with hyperinflammation and ARDS⁹, a study from Italy did not show significant mortality benefit¹⁰. While randomized controlled trials are awaited, there is an urgency to explore therapeutic options that can help to avert ICU admissions, especially given the limited capacity in resource-constrained settings. Hence, we would like to report our clinical experience of the management of ARDS and hyperinflammation with the IL-6 inhibitor Tocilizumab which will be the first from a lower-middle-income country (LMIC).

METHODS

We conducted a retrospective descriptive study on COVID-19 patients with ARDS and hyperinflammation admitted to the Aga Khan University Hospital (AKUH); a 700-bedded tertiary care hospital. Cytokine storm or Hyperinflammation was defined as either a serum CRP ≥ 100

mg/L or a ferritin ≥ 900 ng/mL or both⁶. ARDS was defined as per WHO definition as having “onset within 1 week of a known clinical insult or new or worsening respiratory symptoms, chest imaging (radiograph, CT scan, or lung ultrasound) with bilateral opacities, not fully explained by volume overload, lobar or lung collapse, or nodules and respiratory failure not fully explained by cardiac and $\text{PaO}_2/\text{Fio}_2 < 300 \text{ mmHg}$ ”¹¹. Patients were excluded if they had transaminitis (ALT of greater than 3 times upper normal limit) and/or ongoing bacterial infection or tuberculosis. Demographics and clinical data from the hospital medical records were collected using a structured proforma. The outcomes assessed included in-hospital mortality, length of stay, and development of nosocomial infection during hospitalization. The study was submitted for ethical approval to the AKUH ethical review committee and received exemption (ERC reference number: 2020-3650-10382). The data was anonymized, and no personal identifiers were recorded.

Categorical variables such as gender, development of nosocomial infection were described as proportions, and continuous variables like age and length of hospital stay were described using mean, median, and interquartile range (IQR) values. Proportions for categorical variables as mentioned above were compared using the χ^2 test or Fisher exact test where appropriate. Statistical analysis was performed using STATA ver 12. A p-value of less than .05 was considered statistically significant.

RESULTS

A total of 244 patients of COVID-19 were admitted from Feb 26th to May 15th 2020, out of which 107 met WHO criteria for ARDS. Of these, 30 patients with ARDS who also met the criteria for hyperinflammation and qualified to receive tocilizumab. The clinical characteristics and outcomes of these 30 patients are summarized in Table 1. The mean age was 62.5 years (SD: 13.5) and the majority were male (83%). None of the patients had a rheumatological illness. The median dose of tocilizumab was 600mg (Range: 320 – 680 mg). No adverse effects were observed during or post-infusion. Twenty-one patients (70%) also received concomitant systemic steroids (intravenous methylprednisolone). Of the 30 patients, 7 died and 20 recovered while information was missing on 3 patients who left against medical advice. The

mean length of hospitalization was 12 days (SD: 6.7). The mean CRP pre and post tocilizumab treatment in those who died compared to those who survived are shown in Figure 1. Ten patients required ICU admission and intermittent positive pressure ventilation (IPPV) whereas 14 patients were managed on Non-invasive ventilation (NIV). Nine patients developed nosocomial infections, of which 6 of were hospital-acquired pneumonia (three with multi-drug resistant (MDR) acinetobacter, 2 with MDR *Pseudomonas aeruginosa* and one with methicillin resistant *Staphylococcus aureus* (MRSA). Additionally, 7 patients also isolated aspergillus species from their respiratory specimens out of which 3 patients were diagnosed with COVID-19 associated aspergillosis and 4 were considered to be colonized. Mortality was higher in patients who developed a nosocomial infection (p-value: 0.005) and who required IPPV (p-value: 0.023).

DISCUSSION

In a recent debriefing, WHO has raised alarm over the numbers of cases that are exponentially increasing in the lower-middle-income countries (LMICs). It is a major cause of concern particularly since the capacities of developed countries have been overwhelmed. Since the development of a vaccine is unlikely in the near future, the focus has been on treatment and compassionate use of certain medications. Tocilizumab is a monoclonal antibody targeting the receptor of IL-6; a pro-inflammatory cytokine involved in the pathogenesis of ARDS seen with COVID-19⁸. Data is urgently needed from developing countries as a “one-size fits all” strategy cannot be used in resource-constrained regions where healthcare capacities are already overstretched¹². Moreover, whether tocilizumab is a cost-effective option in developing countries also requires exploration because of the differences in case fatality rates from the different parts of the world suggesting that same approaches may not be regionally relevant. We conducted an observational study describing patient outcomes in those critically ill patients of COVID-19 who received tocilizumab intravenously for hyperinflammation and ARDS. Most of the data regarding its off-label use in COVID-19 has been from studies conducted in China and parts of Europe (Table 2). The age and gender distribution of our patient population were similar to those reported in studies from China and Italy^{10,13}. The mortality data has been conflicting from Italy with Colaneri M et al. reporting no benefit¹⁰ whereas the Sciascia S et al.

showing reduced mortality in those who received treatment with tocilizumab ¹⁴. On the other hand outcomes have been consistently reported to be good in studies from China, at the time of submission, some had not been peer-reviewed and others did not take into account concomitant treatments ^{9,13}. Our study has reported a mortality of 23% which is similar to other studies, but we also report concomitant use of systemic steroids in 70% of the patients which may have contributed in immunomodulation. None of the studies so far have reported nosocomial infection or aspergillus infection or colonization. Since IL-6 antagonism can potentially predispose to worse outcomes in infections, this is an important observation in our study and can have implications in developing countries where there is a higher incidence of multi-drug resistant infections.

Our study is limited because of small sample size and single-center design but this is expected given the availability and cost of tocilizumab in our region which makes it imperative to understand its potential for use in our setting. All the studies exploring outcomes with tocilizumab are limited due to their small sample sizes and observational design highlighting the need for randomized controlled trials. However, given the rapidity of the spread of COVID-19 infection, real-time data is needed particularly from LMICs which are about to see the peak in the number of cases.

Conclusion

Our study supports the use of tocilizumab in a select patient population with COVID-19 and recommends monitoring of nosocomial infections and opportunistic infections in COVID-19 patients who receive the medication which may lead to adverse outcomes in these patients.

Table 1: Clinical characteristics and outcomes of COVID-19 patients who received Tocilizumab

Demographics			
Number patients (N)	30		
Age mean $\pm$ SD years	62.5 $\pm$ 13.5		
Gender n(%)	Male	Female	
	25 (83%)	5 (17%)	
Length of stay mean $\pm$ SD days	12 $\pm$ 6.7		
Pre-treatment ventilator status			
Assisted ventilation n(%)	IPPV	NIV	None
	10 (33%)	14 (48%)	6 (20%)
Drug management			
Tocilizumab Dose Median (Range) mg	600 (320-680)		
Concomitant steroids n(%)	21 (70%)		
Outcome			
Acute phase reactant response	Pre-tocilizumab	Post-tocilizumab	
CRP mean $\pm$ SD mg/dl	217.5 $\pm$ 64.6	98.4 $\pm$ 56.3	
Immunosuppression			
Nosocomial Infection n(%)	9 (30%)		
Aspergillus infection/colonization n(%)	7 (24%)		
Final outcome	Dead	Alive	Unknown
n (%)	7 (23%)	20 (66%)	3 (10%)

Table 2: Summary of studies describing experience with Tocilizumab use in severe COVID-19 infection

Study	Country of study	Number of patients who received IV TOCILIZUMAB	Study design	Outcomes	Conclusion
Luo P et al. ¹³	China	15	Observational	3/5 (20%) mortality, 2/15 with disease aggravation	Good response in patients with Tocilizumab
Colaneri M et al. ¹⁰	Italy	21	Observational	5/21 (24%) Day-7 mortality at Day 7. No difference compared with those who didn't get Tocilizumab	Tocilizumab administration did not reduce ICU admission and mortality rate
Sciascia S et al. ¹⁴	Italy	34	Pilot prospective open single-arm	4/31 (12%) mortality in Tocilizumab arm.	May benefit in severe disease
Xu X et al. ¹⁵	China	21	Observational	No mortality	Good outcome
Van Kraaij et al. ¹⁶	Netherlands	1	Case report	Survived	Good outcome
Klopfenstein T et al. ¹⁷	France	20	Case Control	25% mortality in Tocilizumab group versus 48% in no Tocilizumab group	Good outcome

SUPPLEMENTAL MATERIAL

FIGURE LEGEND

Figure 1: Comparison of C - reactive protein levels before and after administration of intravenous Tocilizumab in patients who died versus survived

REFERENCES

1. Mahase E. Covid-19: WHO declares pandemic because of "alarming levels" of spread, severity, and inaction. *BMJ*. 2020;368:m1036.
2. Worldometer. COVID-19 Coronavirus Pandemic. 2020; <https://www.worldometers.info/coronavirus/>.
3. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. *Science*. 2020;368(6490):473-474.
4. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. *Clinical Infectious Diseases*. 2020.
5. Chen C, Zhang X, Ju Z, He W. Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies. *Zhonghua shao shang za zhi= Zhonghua shaoshang zazhi= Chinese journal of burns*. 2020;36:E005-E005.
6. Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. *The Lancet Rheumatology*.
7. McGonagle D, Sharif K, O'Regan A, Bridgewood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. *Autoimmunity reviews*. 2020;19(6):102537.
8. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. *JAMA*. 2020.
9. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. *Int J Antimicrob Agents*. 2020:105954.
10. Colaneri M, Bogliolo L, Valsecchi P, et al. Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo Covid19 Registry (SMACORE). *Microorganisms*. 2020;8(5).
11. Organization WH. *Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected*. 2020.
12. The Lancet Infectious D. COVID-19: endgames. *The Lancet Infectious Diseases*. 2020;20(5):511.
13. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. *J Med Virol*. 2020.
14. Sciascia S, Apra F, Baffa A, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. *Clin Exp Rheumatol*. 2020.
15. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. *Proc Natl Acad Sci U S A*. 2020;117(20):10970-10975.
16. van Kraaij TD, Mostard RL, Ramiro S, et al. Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome. *Eur J Case Rep Intern Med*. 2020;7(5):001675.
17. Klopfenstein T, Zayet S, Lohse A, et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. *Med Mal Infect*. 2020.